The Life Sciences team advised Magenta Therapeutics (Nasdaq: MGTA) (“Magenta”) on the completion of its merger with Dianthus Therapeutics (“Dianthus”) following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the “combined company.”
The combined company will operate under the name, Dianthus Therapeutics, Inc., and its shares will begin trading on The Nasdaq Capital Market on a post-reverse split, post-merger basis under the ticker symbol "DNTH" effective with the open of business on Tuesday, September 12, 2023.
The Goodwin team was led by Bill Collins, Mike Patrone and Marianne Sarrazin, and included Wei Xu, Stephanie Barbanell, Loren Goodman, Stephanie Isaia, Janet Hsueh, Immanuel Kim, Alexandra Singer, Andrew Goodman, Sarah Bock, Morgan Frisoli, Brian Mukherjee, Tim Worden, Alex Varond, Ed Holzwanger, Caroline Bullerjahn, Jacqueline Klosek and Dan Karelitz.
For additional details on the closing, please read the press release.